

Final - February 25, 2019

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

1600 Clifton Road, NE, Tom Harkin Global Communications Center, Kent "Oz" Nelson Auditorium

Atlanta, Georgia 30329

February 27-28, 2019

AGENDA ITEM

PRESIDER/PRESENTER(S)

Wednesday, February 27

8:00	Welcome & Introductions	Dr. Jose Romero (ACIP Chair) Dr. Amanda Cohn (ACIP Executive Secretary; CDC)
8:20	Japanese Encephalitis Vaccine	
	Introduction	Dr. Chip Walter (ACIP, WG Chair)
	Background and review	Dr. Susan Hills (CDC/NCEZID)
	Updated recommendations for U.S. travelers	Dr. Susan Hills (CDC/NCEZID)
	Accelerated primary series in adults	Dr. Susan Hills (CDC/NCEZID)
	Booster dose recommendations	Dr. Susan Hills (CDC/NCEZID)
9:20	Break	
9:30	Anthrax Vaccines	
	Introduction	Dr. David Stephens (ACIP, WG Chair)
	AV7909 (NuThrax)	Dr. William Bower (CDC/NCEZID)
	Preexposure AVA booster dose interval	Dr. William Bower (CDC/NCEZID)
10:30	Break	
10:40	Influenza Vaccines	
	Introduction	Dr. Chip Walter
	Surveillance update	Ms. Lynnette Brammer (CDC/NCIRD)
	VE update	Dr. Brendan Flannery (CDC/NCIRD)
	Afluria quadrivalent for children aged 6 through 59 months	Dr. Gregg Sylvester (Seqirus)
	Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink	Dr. James Donahue (Marshfield Clinic)
	Summary and work group considerations	Dr. Lisa Grohskopf (CDC/NCIRD)
12:00	Lunch	
1:00	Human Papillomavirus Vaccines	
	Introduction	Dr. Peter Szilagyi (ACIP, WG Chair)
	Overview and background	Dr. Lauri Markowitz (CDC/NCIRD)
	Impact and cost effectiveness of mid-adult HPV vaccination	Dr. Marc Brisson (Laval University)
	Overview of health economic results from 4 modeling groups	Dr. Harrell Chesson (CDC/NCHHSTP)
	Mid-adult HPV vaccination: patient values and acceptability	Dr. Nancy McClung (CDC/NCIRD)
	Program and vaccine provider surveys	Dr. Elissa Meites (CDC/NCIRD)
	Work group considerations	Dr. Lauri Markowitz (CDC/NCIRD)
2:30	Break	
2:40	Combination Vaccines	
	Introduction	Dr. Kelly Moore (ACIP, WG Chair)
	Immunogenicity and safety of a pediatric hexavalent vaccine	Dr. Andrew Lee (Merck)
	Hib vaccines in AI/AN population	Dr. Laura Hammitt (Johns Hopkins University)
	Summary, review of work group considerations	Dr. Sara Oliver (CDC/NCIRD)
3:30	Break	
3:40	Public Comment	
4:55	Break	
5:00	VOTES	
	Japanese Encephalitis Vaccine	Dr. Susan Hills (CDC/NCEZID)
	Anthrax Vaccines	Dr. William Bower (CDC/NCEZID)
5:30	Adjourn	

Final - February 25, 2019

Thursday, February 28

8:00 Agency Updates & Unfinished Business		Dr. Nancy Messonnier (CDC/NCIRD); <i>Ex Officio</i> Members
CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NIH, NVPO		
8:30 Pneumococcal Vaccines		
Introduction		Dr. Grace Lee (ACIP, WG Chair)
PCV13 direct and indirect effects on serotype 3 disease		Dr. Tamara Pilishvili (CDC/NCIRD)
PCV13 direct effects on pneumonia hospitalizations in adults		Dr. Fernanda Lessa (CDC/NCIRD)
Comparison of economic analyses of PCV13 use among adults ≥65 years old		Dr. Andrew Leidner (CDC/NCIRD)
GRADE and Evidence to Recommendations (EtR) for PCV13 use among adults ≥65 years old in the context of indirect effects experience to date		Dr. Almea Matanock (CDC/NCIRD)
10:30	Break	
10:40 Meningococcal Vaccines		
Introduction		Dr. David Stephens (ACIP, WG Chair)
Immunogenicity and safety of a MenB-FHbp booster dose		Dr. Paul Balmer (Pfizer)
Immunogenicity and safety of a MenB-4C booster dose		Dr. Phil Watson (GSK)
GRADE and Evidence to Recommendations Framework for MenB booster doses		Dr. Catherine Bozio (CDC/NCIRD)
Work Group interpretation of data, considerations, and next steps		Dr. Sarah Mbaeyi (CDC/NCIRD)
11:55	Lunch	
1:00 Zoster Vaccines		
Introduction		Dr. Kelly Moore (ACIP, WG Chair)
Zoster vaccine uptake and supply		Dr. Kathleen Dooling (CDC/NCIRD)
RZV safety update		Dr. Tom Shimabukuro (CDC/NCEZID)
1:40 Hepatitis Vaccines		
Introduction		Dr. Kelly Moore (ACIP, WG Chair)
Background: HepA vaccines and persons with HIV infection		Dr. Mark Weng (CDC/NCHHSTP)
GRADE: Use of HepA vaccines among persons with HIV infection		Ms. Alaya Koneru (CDC/NCHHSTP)
Evidence to Recommendation Framework: Use of HepA vaccines among persons with HIV infection		Dr. Mark Weng (CDC/NCHHSTP)
2:35 Vaccine Supply		
2:40 Adjourn		

Acronyms

AI/AN	American Indian/Alaska Native
AVA	Anthrax vaccine absorbed
CDC	Centers for Disease Control & Prevention
CMS	Centers for Medicare and Medicaid Services
DoD	Department of Defense
DVA	Department of Veterans Affairs
EtR	Evidence to Recommendations Framework
FDA	Food and Drug Administration
GRADE	Grading of Recommendations Assessment, Development and Evaluation
Hib	<i>Haemophilus influenzae</i> type b
HRSA	Health Resources and Services Administration
IHS	Indian Health Service
MenB	Serogroup B meningococcal vaccine
NCHHSTP	National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD	National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID	National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NVPO	National Vaccine Program Office
PCV13	13-valent pneumococcal conjugate vaccine
RZV	Recombinant zoster vaccine
WG	Work Group